UITM-CaixaResearch presents promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma

by VHIO

Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with a manageable safety profile and promising antitumour activity, especially in patients with...

Read more

Adding a genetically modified virus to immunotherapy demonstrates antitumour activity in previously treated melanoma patients

by VHIO

Initial data from the IGNYTE clinical trial demonstrate that the combination of the oncolytic virus RP1 and nivolumab (PD-1 immune checkpoint inhibitor) provides durable and clinically significant ant...

Read more

La caracterización genómica de mieloma múltiple de alto riesgo desvela nuevos marcadores de resistencia y progresión

by CIBERONC - Centro de Investigación Biomédica en Red, Cáncer

Un estudio colaborativo supone la primera caracterización genética de pacientes con MM de alto riesgo tratados con un esquema terapéutico intensivo, en el que se describe una posible relación entr...

Read more

First targeted radioligand therapy to demonstrate significant and clinically meaningful impact in first-line advanced gastroeneropancreatic neuroendocrine tumors

by VHIO

It has been demonstrated that first-line treatment with 177LU-DOTATATE combined with long-acting octreotide significantly improves progression-free survival (PFS) in patients with recently diagnosed s...

Read more

Vall d'Hebron has linked a poor microbiome to poorer recovery after liver transplantation

by Vall d’Hebron

People with more complications and a worse prognosis continue to have dysbiosis, a change in the bacterial microbiota, one year after the operation. In contrast, people with a more positive post-surge...

Read more

ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3-mut AML patients at EHA-2024

by Oryzon Genomics

Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity

Read more

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit

by Ysios Capital

aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vessel

Read more

INCLIVA participa en un ensayo para determinar la dosis óptima de un anticuerpo en el tratamiento de la trombocitemia esencial y la mielofibrosis

by INCLIVA

El ensayo analiza un anticuerpo biespecífico frente a la Calreticulina mutada y el CD3 de los linfocitos para frenar estos trastornos hematológicos

Read more

Último paciente del estudio: Laminar Pharmaceuticals S.A. completa el reclutamiento para CLINGLIO, el ensayo clínico de fase 2b/3 de ácido idroxioleico (LAM561) en combinación con RT y TMZ para adultos con glioblastoma de nuevo diagnóstico

by Laminar Pharma

Laminar Pharmaceuticals S.A. se complace en anunciar que el reclutamiento de pacientes para el estudio CLINGLIO (NCT04250922) se ha cerrado después de que 140 pacientes adultos se hayan reclutado con...

Read more

Novel T-cell bispecific antibody shows promise in retriggering the immune response to combat metastatic colorectal cancer

by VHIO

First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as a single agent with or without chemotherapy, a...

Read more

Hospital del Mar Participates in Two Studies Presented at ASCO that Change the Approach for Certain Lung Cancer Patients

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

These are two international clinical trials, LAURA and ADRIATIC, which confirm the positive effect of consolidation with systemic therapies following the combination of chemotherapy in two patient pop...

Read more

Nuevo proyecto de investigación para mejorar la supervivencia de los pacientes de cáncer de hígado

by Professional Newco

El proyecto contempla un ensayo clínico donde los participantes del mismo sean tratados con dos inmunoterapias conjuntamente tanto antes como después de la extirpación quirúrgica del tumor. Por ot...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream